Christian Boada1,2, Roman Sukhovershin1, Roderic Pettigrew2,3, John P Cooke1. 1. RNA Therapeutics Program, Department of Cardiovascular Sciences, Houston Methodist Academic Institute. 2. Department of Engineering Medicine, Texas A&M Health Science Center and Houston Methodist, Houston. 3. Department of Biomedical Engineering, Texas A&M University, College Station, Texas, USA.
Abstract
PURPOSE OF REVIEW: The development of mRNA vaccines against coronavirus disease 2019 has brought worldwide attention to the transformative potential of RNA-based therapeutics. The latter is essentially biological software that can be rapidly designed and generated, with an extensive catalog of applications. This review aims to highlight the mechanisms of action by which RNA-based drugs can affect specific gene targets and how RNA drugs can be employed to treat cardiovascular disease, with the focus on the therapeutics being evaluated in clinical trials. The recent advances in nanotechnology aiding the translation of such therapies into the clinic are also discussed. RECENT FINDINGS: There is a growing body of studies demonstrating utility of RNA for targeting previously 'undruggable' pathways involved in development and progression of cardiovascular disease. Some challenges in RNA delivery have been overcome thanks to nanotechnology. There are several RNA-based drugs to treat hypercholesterolemia and myocardial infarction which are currently in clinical trials. SUMMARY: RNA therapeutics is a rapidly emerging field of biotherapeutics based upon a powerful and versatile platform with a nearly unlimited capacity to address unmet clinical needs. These therapeutics are destined to change the standard of care for many diseases, including cardiovascular disease.
PURPOSE OF REVIEW: The development of mRNA vaccines against coronavirus disease 2019 has brought worldwide attention to the transformative potential of RNA-based therapeutics. The latter is essentially biological software that can be rapidly designed and generated, with an extensive catalog of applications. This review aims to highlight the mechanisms of action by which RNA-based drugs can affect specific gene targets and how RNA drugs can be employed to treat cardiovascular disease, with the focus on the therapeutics being evaluated in clinical trials. The recent advances in nanotechnology aiding the translation of such therapies into the clinic are also discussed. RECENT FINDINGS: There is a growing body of studies demonstrating utility of RNA for targeting previously 'undruggable' pathways involved in development and progression of cardiovascular disease. Some challenges in RNA delivery have been overcome thanks to nanotechnology. There are several RNA-based drugs to treat hypercholesterolemia and myocardial infarction which are currently in clinical trials. SUMMARY: RNA therapeutics is a rapidly emerging field of biotherapeutics based upon a powerful and versatile platform with a nearly unlimited capacity to address unmet clinical needs. These therapeutics are destined to change the standard of care for many diseases, including cardiovascular disease.
Authors: Federica Fogacci; Nicola Ferri; Peter P Toth; Massimiliano Ruscica; Alberto Corsini; Arrigo F G Cicero Journal: Drugs Date: 2019-05 Impact factor: 9.546
Authors: Daniel Gaudet; Veronica J Alexander; Brenda F Baker; Diane Brisson; Karine Tremblay; Walter Singleton; Richard S Geary; Steven G Hughes; Nicholas J Viney; Mark J Graham; Rosanne M Crooke; Joseph L Witztum; John D Brunzell; John J P Kastelein Journal: N Engl J Med Date: 2015-07-30 Impact factor: 91.245
Authors: Jonathan O Martinez; Roberto Molinaro; Kelly A Hartman; Christian Boada; Roman Sukhovershin; Enrica De Rosa; Dickson Kirui; Shanrong Zhang; Michael Evangelopoulos; Angela M Carter; James A Bibb; John P Cooke; Ennio Tasciotti Journal: Theranostics Date: 2018-01-05 Impact factor: 11.556
Authors: Marvin Krohn-Grimberghe; Michael J Mitchell; Maximilian J Schloss; Omar F Khan; Gabriel Courties; Pedro P G Guimaraes; David Rohde; Sebastian Cremer; Piotr S Kowalski; Yuan Sun; Mingchee Tan; Jamie Webster; Karin Wang; Yoshiko Iwamoto; Stephen P Schmidt; Gregory R Wojtkiewicz; Ribhu Nayar; Vanessa Frodermann; Maarten Hulsmans; Amanda Chung; Friedrich Felix Hoyer; Filip K Swirski; Robert Langer; Daniel G Anderson; Matthias Nahrendorf Journal: Nat Biomed Eng Date: 2020-10-05 Impact factor: 25.671